Constantly condensing the truth

In May 2024, he joined Shanghai Lishan Biomedicine Co., LTD

Mr. Du served as a CBER Review Officer at the FDA, responsible for the review of biologics IND and BLA, and has experience managing marketed drugs in more than 30 countries.

Doctor from the University of Florida, Senior Vice President of International New drug development of Arnaud Pharmaceutical, and senior executives of many international large pharmaceutical companies such as Pfizer, Novartis, Sanofi and BMS.